These authors suggested that the restoration of miR-3609 may sensitize breast cancer cells to adriamycin through the blocking of PD-L1 expression and, therefore, miR-3609 could be used as a chemotherapeutic target for breast cancer [74]. The gene discussed is CD274; the disease is breast cancer.